Centre Leon Berard
Centre Leon Berard
Lyon, France34 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Met Non Small Cell Cancer Registry (MOMENT) | cancer, neoplasm | Recruiting | Not stated | 2026-10-02 | NCT05376891 | |
| A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT07213817 | |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-09-25 | NCT05572229 | |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-15 | NCT06899126 | |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland disorder | Recruiting | Phase 1 | 2026-09-02 | NCT04913285 | |
| DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Recruiting | Phase 2 | 2026-08-26 | NCT06059495 | |
| Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, liposarcoma, myxoid liposarcoma, neoplasm, sarcoma, synovial sarcoma | Active, not recruiting | Phase 2 | 2026-08-26 | NCT04044768 | |
| Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-11 | NCT02889523 | |
| Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, epithelial neoplasm, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-08-10 | NCT06840834 | |
| Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Not yet recruiting | Phase 2 | 2026-08-03 | NCT07340619 | |
| Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy | Primary Non-metastatic Breast Cancer; Who Remain Disease-free | Active, not recruiting | Phase 3 | 2026-07-31 | NCT01805271 | |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, head and neck squamous cell carcinoma, intestinal disorder, neoplasm, non-small cell lung carcinoma, rectal disorder, squamous cell carcinoma, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-07-29 | NCT03526835 | |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-07-02 | NCT06819007 | |
| International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia | Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-06-29 | NCT02724163 | |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, arthropathy, connective tissue neoplasm, disease of the tendon, giant cell tumor, muscle tissue disorder, musculoskeletal system disorder, neoplasm, synovitis, tenosynovial giant cell tumor, tenosynovial giant cell tumor, diffuse type | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-25 | NCT03069469 | |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-06-22 | NCT05696626 | |
| A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa. | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Recruiting | Phase 2 | 2026-06-02 | NCT06022159 | |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-12 | NCT03609047 | |
| Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-02-20 | NCT05378204 | |
| Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer | HER2-positive Breast Cancer; Operable Breast Cancer | Active, not recruiting | Phase 2 | 2025-11-26 | NCT03571633 | |
| Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | Metastatic Breast Cancer With a Isolated Brain Progression | Active, not recruiting | Phase 2 | 2025-11-17 | NCT05041842 | |
| A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 | 2025-09-26 | NCT06540391 | |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-09-12 | NCT03515798 | |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2025-08-01 | NCT03235245 | |
| iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03350126 |